CA2465869A1 - Therapie anti-mnemonique pour syndromes d'hypermemoire - Google Patents

Therapie anti-mnemonique pour syndromes d'hypermemoire Download PDF

Info

Publication number
CA2465869A1
CA2465869A1 CA002465869A CA2465869A CA2465869A1 CA 2465869 A1 CA2465869 A1 CA 2465869A1 CA 002465869 A CA002465869 A CA 002465869A CA 2465869 A CA2465869 A CA 2465869A CA 2465869 A1 CA2465869 A1 CA 2465869A1
Authority
CA
Canada
Prior art keywords
disorder
drug
antimnemonic
cue
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002465869A
Other languages
English (en)
Inventor
John L. Haracz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HARACZ JOHN
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2465869A1 publication Critical patent/CA2465869A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une thérapie anti-mnémonique pour le traitement de troubles comportementaux tels que la toxicomanie, des troubles obsessivo-compulsifs, le syndrome de Tourette, des troubles de stress post-traumatiques (SSPT), des troubles bipolaires, la dépression, la schizophrénie, des troubles de l'anxiété et des troubles de la personnalité. La thérapie anti-mnémonique peut impliquer la réactivation de souvenirs induits par la psychothérapie ou des signaux en association avec l'administration de médicaments anti-mnémoniques.
CA002465869A 2001-11-06 2002-11-05 Therapie anti-mnemonique pour syndromes d'hypermemoire Abandoned CA2465869A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33271301P 2001-11-06 2001-11-06
US60/332,713 2001-11-06
PCT/US2002/035524 WO2003039468A2 (fr) 2001-11-06 2002-11-05 Therapie anti-mnemonique pour syndromes d'hypermemoire

Publications (1)

Publication Number Publication Date
CA2465869A1 true CA2465869A1 (fr) 2003-05-15

Family

ID=23299527

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002465869A Abandoned CA2465869A1 (fr) 2001-11-06 2002-11-05 Therapie anti-mnemonique pour syndromes d'hypermemoire

Country Status (3)

Country Link
AU (1) AU2002354041A1 (fr)
CA (1) CA2465869A1 (fr)
WO (1) WO2003039468A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298361B2 (en) 2012-07-12 2022-04-12 Emalex Biosciences, Inc. Fused benzazepines for treatment of Tourette's Syndrome

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
WO2006034187A2 (fr) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Utilisation de memantine (namenda) pour traiter l'autisme, les etats compulsifs et impulsifs
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
WO2008045641A2 (fr) * 2006-10-10 2008-04-17 The University Of Chicago Composition et procédé permettant de traiter l'alcoolisme et les addictions à d'autres substances
US20110046120A1 (en) * 2006-10-26 2011-02-24 Mclean Hospital Corporation Treatment of impulse control disorders
WO2016061320A2 (fr) * 2014-10-15 2016-04-21 Rowan University Thérapie timber pour le trouble du stress post-traumatique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112487C (fr) * 1991-06-26 2003-04-15 James W. Young Methode et compositions pour le traitement des vomissements, des nausees et d'autres troubles a l'ondansetron optiquement pur r(+)
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
US5863934A (en) * 1995-09-21 1999-01-26 Amy F. T. Arnsten Use of lofexidine in the treatment of behavioral disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298361B2 (en) 2012-07-12 2022-04-12 Emalex Biosciences, Inc. Fused benzazepines for treatment of Tourette's Syndrome

Also Published As

Publication number Publication date
AU2002354041A1 (en) 2003-05-19
WO2003039468A2 (fr) 2003-05-15
WO2003039468B1 (fr) 2003-11-27
WO2003039468A3 (fr) 2003-10-23

Similar Documents

Publication Publication Date Title
US20040087576A1 (en) Antimnemonic therapy for hypermemory syndromes
Brown Ibogaine in the treatment of substance dependence
Singleton et al. Mechanisms of alcohol craving and their clinical implications
US20080194631A1 (en) Medicament For the Treatment of Central Nervous System Disorders
Bishop et al. Psychopharmacological analysis of implicit and explicit memory: a study with lorazepam and the benzodiazepine antagonist flumazenil
CA2465869A1 (fr) Therapie anti-mnemonique pour syndromes d'hypermemoire
LeCocq et al. Considering drug-associated contexts in substance use disorders and treatment development
LIBERMAN et al. Drugs and behavior analysis
Tomek et al. Social influences in animal models of opiate addiction
Karczmar Exploring the vertebrate central cholinergic nervous system
Lutz et al. Alcohol conditioned contexts enhance positive subjective alcohol effects and consumption
Dale et al. Drug therapy to aid in smoking cessation: tips on maximizing patients' chances for success
JP2024507492A (ja) 精神療法を補助するためのメスカリン及びメスカリン類似体（スカリン）の効果
Lee et al. Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy
Evans et al. Smoked heroin in rhesus monkeys: effects of heroin extinction and fluid availability on measures of heroin seeking
Freedlander Ibogaine: A novel anti-addictive compound
Burgess Behavioral Effects of Opioid Analgesics in the Presence or Absence of Chronic Neuropathic Pain
Maremmani et al. Antagonist opioid medications in mental illness: State of art and future perspectives
Kosten et al. Stimulants and related drugs
Zafar Ketamine and Phencyclidine Reward and Sensitization in Adult and Adolescent Rats
McNealy et al. The co-use of nicotine and prescription psychostimulants: A comprehensive review of their behavioral and neuropharmacological interactions
Garg et al. Craving in substance use disorders
Sankaran Incubation of Craving: An Analysis of Short-Access Self-Administration Models Without Food Pre-Training
Yee Separate mesolimbic dopaminergic pathways mediate the opposing motivational effects of acute caffeine
O'Neak Pharmacological modulation of nicotine dependence in the rat

Legal Events

Date Code Title Description
FZDE Discontinued